mRNAs of human papillomaviruses (HPV) 16 and 18 were detected in cancer-derived cell lines and genital tract biopsy specimens by a novel hybridization assay. Biotinylated whole genomic HPV DNA probes were hybridized in solution to extracted total nucleic acids. Hybrids between the labeled probes and RNA transcripts were captured on a microplate coated with an antibiotin antibody. Bound hybrids were incubated with a j8-galactosidase-labeled monoclonal antibody to DNA-RNA hybrids and measured by the addition of a fluorogenic substrate. HPV 18 and HPV 16 mRNAs were detected in nucleic acids from 2.3 x i03 HeLa cells and 104 SiHa cells, respectively. The specificity of the assay for mRNA was demonstrated by the low reactivity of nucleic acids from SiHa cells after treatment with T1 RNase and by the selective reactivity of cellular nucleic acids which bound to an oligo(dT) column. With HPV 16 subgenomic probes, E6-E7 transcripts but not L1-L2 transcripts were detected in SiHa cells. Tests of 58 biopsy specimens from 31 patients showed that the detection of HIPV 16 and HPV 18 transcripts in tissue specimens was feasible. Analysis of biopsy specimens with subgenomic probes revealed HPV 16 E6-E7 transcripts in all specimens that reacted with the whole genomic probe, while L1-L2 transcripts were found infrequently.
Human papillomaviruses (HPV) are etiological agents of cutaneous and mucosal papillomas (18) . HPV 16 and HPV 18 have also been implicated in the genesis of anogenital carcinomas (6, 14, 17) . Since these viruses cannot be propagated in cell cultures, the diagnosis of HPV infections is usually established by the detection of viral genetic material in tissue specimens by nucleic acid hybridization techniques. HPV are double-stranded DNA viruses, and the most common hybridization methods used for viral diagnosis are dot blot and Southern blot hybridization methods (29) . The detection of HPV RNA, on the other hand, has received little attention, although the presence of specific mRNA has been described in cervical carcinoma cell lines (32, 42) and in a limited number of clinical specimens (13, 34) . mRNA has most commonly been detected by in situ hybridization (7, 37) or mixed-phase hybridization assays (2, 13, 21, 34, 39) . The utility of these techniques for routine diagnosis and large epidemiological studies is limited. Both methods are labor-intensive and rely on the use of radioisotopes. The manipulation and disposal of radioactive material are hazardous and inconvenient. In addition, radiolabeled probes have a short functional half-life and therefore must be regenerated regularly. A further disadvantage of mixedphase assays with nitrocellulose filters is that nucleic acids bound to filters have unfavorable reaction kinetics (15) . Assays with filters are also difficult to standardize because the preparation of filters and their performance characteristics are highly variable. We have recently described a highly sensitive, nonisotopic solution hybridization assay for the detection of RNA which overcomes many of the technical problems inherent in other RNA detection methods (12, 40) . In this assay, hybrids between a biotinylated DNA probe and specific RNA sequences are captured on a microtiter plate coated with an antibody to biotin. Bound hybrids are detected with an enzyme-labeled monoclonal antibody against DNA-RNA hybrids (5, 43) . We report here the use of this assay for the detection of mRNAs from HPV 16 and HPV 18 in cell lines and biopsy specimens. MATERIALS Samples were extracted once with a 1:1 mixture of buffered phenol and chloroform-isoamyl alcohol (24:1) and once with chloroform-isoamyl alcohol. Nucleic acids were precipitated in 95% cold ethanol-0.3 M sodium acetate at -70°C for 1 h (23) . After centrifugation at 10,000 x g for 15 min at 40C, samples were air dried and resuspended in DEPC-H20 containing 0.5% SDS. Biopsy specimens were thawed, minced, and ground. The specimens were resuspended in 300 [lI of 10 mM Tris (pH 7.4)-i mM EDTA (TE) containing 1% SDS and processed as described above for tissue culture cells. Total nucleic acids were quantitated by spectrophotometry at 260 nm, and measured amounts of nucleic acids were quantitated by spectrophotometry at 260 nm, and measured amounts of nucleic acids were tested in the hybridization assays.
Total RNA from cultured cells was prepared by the single-step acid guanidinium thiocyanate-phenol-chloroform extraction method (8) . In brief, 106 cells were lysed in 1 ml of Solution hybridization assay and enzyme inmunoassay for DNA-RNA hybrids. The hybridization assay and enzyme immunoassay were performed as described previously (11, 12) . HPV 16 and HPV 18 plasmids were labeled with bio-11-dUTP (Enzo Biochem Inc., New York, N.Y.) in a standard nick translation procedure (12, 20 Isotopic hybridization for viral RNA. A dot blot procedure (4) for RNA detection was performed as follows. Plasmid pgl6 was labeled by a nick translation reaction with
[32P]dCTP to a specific activity of 2 x 108 cpm/,ug (27) . RNA was extracted by the single-step guanidinium method, diluted in 8x SSC containing 3.7% formaldehyde, and incubated at 60°C for 15 min. The samples were applied to nitrocellulose filters with a manifold apparatus (Slot Blotter; Schleicher & Schuell). The filters were baked for 2 h at 80°C and prehybridized for 4 h at 42°C in a solution of deionized formamide-5x Denhardt's solution-3 x SSC-0.1% SDS-0.1 mM EDTA-1 mM sodium PPi-10 mM HEPES buffer (pH 7.0)-100 pug of salmon sperm DNA per ml. The hybridization solution was identical to the prehybridization solution, except for the inclusion of 10% dextran sulfate as a volume excluder and 107 cpm of a heat-denatured 32P-labeled HPV 16 probe per ml. After incubation overnight at 42°C, the filters were washed three times, first at room temperature in 2x SSC, then at 60°C in 0.lx SSC-0.1% SDS, and finally at room temperature in 0.1 x SSC. The filters were exposed to X-ray film for 2 days at -70°C with one intensifying screen.
StAtistical analyses. Statistical analyses were done with the unpaired Student t test (41) .
RESULTS
Initial experiments were aimed at determining the sensitivity and specificity of the solution hybridization assayenzyme immunoassay for the detection of HPV 16 and HPV 18 transcripts from cancer-derived cell lines. Integrated HPV genomes in cancer-derived cell lines have been shown to actively transcribe mRNA (21, 24, 32, 42) . Total nucleic acids were extracted from SiHa or HeLa cells, which contained HPV 16 or HPV 18, respectively, and were serially diluted in DEPC-H20 containing 0.5% SDS. To maintain a total of 1 pug of nucleic acid per assay, we added the detection cutoff values (mean reactivity of samples devoid of HPV sequences plus 3 standard deviations) were calculated for the HPV 16 (>112 fu) and HPV 18 (>115 fu) assays. The reactivities of nucleic acids extracted from 13 specimens that were positive for HPV other than HPV 16 and HPV 18 were 63 + 20 fu (range, 32 to 100 fu) with the pgl6 probe and 48 + 25 fu (range, 21 to 110 fu) with the pgl8 probe. These reactivities did not differ significantly from those of the HPV-negative specimens for both probes (P > 0.1). Nucleic acids extracted from 105 Vero cells showed a reactivity of 49 + 3 fu with the pgl6 probe. The three specimens that were positive for HPV 16 DNA were also positive for HPV 16 mRNA and showed reactivities of 354, 500, and 194 fu. One sample also reacted positively with the pgl8 probe (133 fu). Of the two specimens that were positive for HPV 18 DNA, only one was positive for HPV 18 mRNA (918 fu).
An additional 25 biopsy specimens, for which virological data were not available, were also tested in the solution hybridization assay-enzyme immunoassay for HPV 16 and HPV 18 mRNAs (Fig. 5) . Seven samples were positive for HPV 16 mRNA (122 to 332 fu). Five samples were positive for HPV 18 mRNA (133 to 833 fu). The remaining 13 samples HPV 16 mRNA showed reactivities with the T16EP probe ranging from 83 to 152 fu (mean, 112 ± 27 fu). The HPV 16 mRNA-positive samples were significantly more reactive in the assay with the T16EP probe than were the HPV 16 mRNA-negative samples (P < 0.001). Samples negative for HPV 16 mRNA showed a low reactivity in the assay with the T16SB probe for the L1-L2 ORF (mean, 15 ± 6 fu; detection cutoff, 35 fu); two samples that were positive for HPV 16 mRNA gave signals of 50 and 65 fu, and four samples gave signals between 17 and 30 fu. (10) . In addition, the use of a nonisotopic label avoids the biohazard, inconvenience, and cost associated with the use of a radioactive label while achieving a sensitivity comparable to those of 32P-based methods. It should be noted that although a fluorogenic substrate was used in these experiments, equal sensitivity can be achieved with an alkaline phosphatase-labeled antibody and a colorimetric substrate (11) . The low background reactivity of the double-stranded DNA probe in the absence of an RNA target demonstrates the specificity of the monoclonal antibody for DNA-RNA hybrids. The molecular basis for this specificity most likely resides in the difference between the A-form double helix, which is the structural form of DNA-RNA hybrids, and the B-form double helix, which is generally believed to represent native doublestranded DNA (28) .
Transcripts from integrated HPV in cell lines have been characterized previously by Northern (RNA) blotting and cDNA sequencing (19, 22, 30, 31, 36 respectively. The elimination of the signal by treatment with RNase and the selective reactivity of polyadenylated nucleic acids showed that the assay is specific for mRNA. The low reactivity of nucleic acids extracted from samples containing one viral type in assays with a heterologous probe or a control probe derived from plasmid sequences showed that the assays for HPV 16 and HPV 18 mRNAs are specific for the respective viral types. In addition, biopsy specimens containing HPV other than HPV 16 and HPV 18 were negative in the assays for HPV 16 and HPV 18 mRNAs.
In a preliminary analysis of the feasibility of using the solution hybridization assay-enzyme immunoassay for the detection of HPV 16 and HPV 18 transcripts in biopsy specimens, stored specimens from 57 genital tract lesions and a laryngeal papilloma were screened with this method. These specimens were collected routinely over 2 years and were not uniformily tested for HPV. Nevertheless, the results of the solution hybridization assay-enzyme immunoassay with these specimens indicated that the method has potential for the detection of viral RNA in biopsy specimens. For the five specimens previously found positive for HPV 16 or HPV 18 DNA, corresponding transcripts were found in four. The possibility that RNA degradation was responsible for the negative results cannot be excluded, since these specimens had been kept frozen for 2 years. Although continued transcription is not required for carcinogenesis (21, 24) , most investigators have found HPV mRNA in all lesions of the cervix harboring HPV DNA (13, 34, 39) . Both HPV 16 and HPV 18 transcripts were detected in one of these four specimens, although it was previously shown to contain only HPV 16 DNA. Using in situ hybridization techniques, Stoler and Broker described specimens that were positive for HPV mRNA but not for HPV DNA (37) . ViraPap-negative specimens and ViraPap-positive specimens found negative for HPV 16 and HPV 18 by Southern hybridization were uniformily nonreactive in the solution hybridization assay-enzyme immunoassay. For the 25 biopsy specimens not previously tested for HPV, HPV 16 transcripts were found in 7 and HPV 18 transcripts were found in 5. The HPV 16 early-region probe was positive in all instances when the HPV 16 full genomic probe was positive.
The detection of HPV transcripts from the early genes in nucleic acids extracted from human genital tract specimens has been described previously (13, 21, 32, 34) . HPV 16 transcripts from the late region were found in two of the biopsy specimens, but it was not possible to interpret the significance of this observation because the biopsy specimens were not tested for the presence of capsid antigens or for late transcripts by in situ hybridization assays. In a study analyzing mRNA of HPV 16 in precancerous lesions of the vulva by in situ hybridization, a strong hybridization signal was shown in the apical portion of the epithelium of a few lesions with subgenomic probes for the late region (13) .
Whether this transcriptional pattern is specific for HPV in vulvar carcinoma needs to be clarified by further studies. The high frequency of HPV 16 mRNA detection in specimens with high-grade squamous cell lesions of the lower genital tract is consistent with other reports in the literature (21, [34] [35] [36] 39) , but a more systematic study is required to evaluate this technique for its usefulness in the study of clinical material.
RNA detection methods may help resolve controversies about the possible role of HPV in squamous cell carcinomas of the lower genital tract. The link between HPV and cancer is based on laboratory studies demonstrating the transforming properties of these viruses (3) and on epidemiological studies reporting the detection of HPV DNA in 80 to 90% of cervical cancer biopsy specimens (25, 26) . However, interpretation of the epidemiological evidence is confounded by the variable frequency of HPV infections in noncancerous lesions. The reported variation in the detection of DNA of HPV 16 , the viral type most commonly associated with cervical cancer, is between 12 and 38.5% for women without cytological abnormalities, depending on the study populations and detection techniques (16, 25, 26, 38) . Recent studies with highly sensitive techniques, such as the polymerase chain reaction, have reported even higher prevalence rates for HPV 16 (33, 45) . If HPV infections are widespread among sexually active individuals, the detection of HPV DNA may not be a useful marker for individuals who are at risk of developing genital cancer. On the other hand, the detection of HPV genomes that are transcriptionally active may be of predictive value, and future studies should address this possibility.
